Underwater endoscopic mucosal resection for colorectal lesions: Can it be an "Underwater" revolution?
- PMID: 35310727
- PMCID: PMC8828230
- DOI: 10.1002/deo2.84
Underwater endoscopic mucosal resection for colorectal lesions: Can it be an "Underwater" revolution?
Abstract
Underwater endoscopic mucosal resection (UEMR) is a newly developed technique for the removal of colorectal, duodenal, esophageal, gastric, ampullary, and small intestinal lesions. We performed a PubMed literature search for articles reporting UEMR outcomes for colorectal polyps. Four randomized controlled trials, nine non-randomized prospective trials, 16 retrospective studies, and 27 case reports were selected for assessment of the efficacy and safety of UEMR. We summarized the therapeutic outcomes of UEMR in each category according to the lesion characteristics [small size (<10 mm), intermediate size (10-19 mm), large size (≥20 mm), recurrent lesion, and rectal neuroendocrine tumor], and calculated the incidence of adverse events among the included articles. As the treatment outcomes for small polyps appeared similar between UEMR and conventional endoscopic mucosal resection (CEMR), UEMR can be a standard procedure for small colorectal polyps suspicious for high-grade dysplasia to avoid incomplete removal of occult invasive cancer by cold snare polypectomy. As UEMR showed satisfactory outcomes for intermediate-size lesions and recurrent lesions after endoscopic resection, UEMR can be a standard procedure for these lesions. Regarding large lesions and rectal neuroendocrine tumors, comparisons of UEMR with current standard methods for them were lacking, and further investigations are warranted. Adverse events appeared comparable or less frequent for UEMR compared with CEMR but still existed. Therefore, careful implementation of this new technique in clinical practice is important for its widespread use.
Keywords: adverse events; colonic neoplasms; colonic polyps; colonoscopic surgery; colonoscopy.
© 2022 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
Conflict of interest statement
Yoji Takeuchi has received honoraria for lectures from Olympus, Boston Scientific Japan, Daiichi‐Sankyo, Miyarisan Pharmaceutical, Asuka Pharmaceutical, AstraZeneca, EA Pharma, Zeria Pharmaceutical, Fujifilm, Kaneka Medix, Kyorin Pharmaceutical, and The Japan Gastroenterological Endoscopy Society. Satoki Shichijo has received honoraria for lectures from Olympus, Boston Scientific Japan, Daiichi Sankyo, EA Pharma, Zeria Pharmaceutical, The Japanese Society of Gastroenterology, and The Japan Gastroenterological Endoscopy Society. Noriya Uedo has received personal fees from Olympus, Fujifilm, Boston Scientific Japan, 3‐D Matrix Ltd., Daiichi Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca, Top Cooperation, and Miyano Medical Instruments. Ryu Ishihara has received personal fees from EA Pharma, AstraZeneca, Ono Pharmaceutical, MSD, Olympus, Daiichi Sankyo, and Fujifilm. These organizations had no role in the design, practice, or analysis in this manuscript. Yoji Takeuchi is an associate editor of DEN Open.
Figures
References
-
- Deyhle P, Seuberth K, Jenny S, Demling L. Endoscopic polypectomy in the proximal colon. Endoscopy 1971; 2: 103–5.
-
- Takeuchi Y, Mabe K, Shimodate Y et al. Continuous anticoagulation and cold snare polypectomy versus heparin bridging and hot snare polypectomy in patients on anticoagulants with subcentimeter polyps: A randomized controlled trial. Ann Intern Med 2019; 171: 229‐37. - PubMed
-
- Binmoeller KF, Weilert F, Shah J, Bhat Y, Kane S. “Underwater” EMR without submucosal injection for large sessile colorectal polyps (with video). Gastrointest Endosc 2012; 75: 1086–91. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials